Overview

Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC

Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
A phase IV study to characterize safety of Elunate® (Fruquintinib) in Chinese patients
Phase:
Phase 4
Details
Lead Sponsor:
Hutchison Medipharma Limited